Drug intelligence / Profile preview

recombinant novel coronavirus subunit vaccine

Development stage: Preclinical
Lead developer: MAXVAX Biotechnology
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

The recombinant novel coronavirus subunit vaccine is a prophylactic vaccine candidate developed by Maxvax (Chengdu Maxvax Biopharmaceuticals) for the prevention of COVID-19. It is a protein subunit vaccine that utilizes recombinant DNA technology to express viral antigens, typically the SARS-CoV-2 spike protein or its receptor-binding domain (RBD). These antigens are designed to stimulate the host's immune system to produce neutralizing antibodies and activate cellular immune responses against the virus. The vaccine is formulated with adjuvants to enhance its immunogenicity. As of the latest reports, the candidate is in the preclinical stage of development.

Other names: Recombinant SARS-CoV-2 subunit vaccine

Targets

RBD (SARS-CoV-2 spike receptor-binding domain)

Beyond the preview

Go deeper on recombinant novel coronavirus subunit vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant novel coronavirus subunit vaccine.

Explore the full profile